Veracyte Q4 Revenues Up 30 Percent on Higher Afirma Gene Expression Classifier Volume

NEW YORK (GenomeWeb) — Veracyte reported after the close of the market on Wednesday that fourth quarter revenues rose 30 percent year over year, driven by strong growth in demand for the company’s Afirma gene expression classifier (GEC) test, which is used in thyroid cancer diagnosis.

For the three-month period ended Dec. 31, Veracyte’s revenues grew to $18.3 million from $14.0 million in Q4 2015, surpassing the analyst consensus estimate of $17.5 million.

Get the full story This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
.

Be the first to comment

Leave a Reply

Your email address will not be published.


*